Black Diamond Therapeutics Inc
$ 2.55
5.81%
24 Feb - close price
- Market Cap 145,286,000 USD
- Current Price $ 2.55
- High / Low $ 2.60 / 2.40
- Stock P/E 6.89
- Book Value 2.21
- EPS 0.37
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.19 %
- 52 Week High 4.94
- 52 Week Low 1.20
About
Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$9.29
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-10 | 2024-11-04 | 2024-08-06 | 2024-05-09 | 2024-03-12 | 2023-11-06 | 2023-08-11 | 2023-05-09 | 2023-03-09 |
| Reported EPS | -0.15 | -0.19 | 0.98 | -0.28 | -0.2753 | -0.36 | -0.35 | -0.34 | -0.45 | -0.52 | -0.57 | -0.59 |
| Estimated EPS | -0.235 | -0.2467 | -0.255 | -0.3117 | -0.37 | -0.39 | -0.43 | -0.47 | -0.49 | -0.54 | -0.61 | -0.63 |
| Surprise | 0.085 | 0.0567 | 1.235 | 0.0317 | 0.0947 | 0.03 | 0.08 | 0.13 | 0.04 | 0.02 | 0.04 | 0.04 |
| Surprise Percentage | 36.1702% | 22.9834% | 484.3137% | 10.17% | 25.5946% | 7.6923% | 18.6047% | 27.6596% | 8.1633% | 3.7037% | 6.5574% | 6.3492% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.18 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BDTX
2026-02-21 06:50:23
Black Diamond Therapeutics (NASDAQ:BDTX) has received an average "Moderate Buy" rating from eight analysts, with an average 1-year price target of $9.33, significantly higher than its current trading price. Despite some recent downgrades, institutional ownership remains high at around 95.5%. The company, focused on precision oncology, is developing allosteric inhibitors including its lead candidate, BDTX-189.
2026-02-04 19:29:50
Piper Sandler has updated its biotech models and 2026 catalyst tracker, resulting in a trimmed price target for Black Diamond Therapeutics, Inc. (BDTX). This adjustment reflects the firm's revised outlook on the company within the broader biotech sector.
2026-02-04 18:58:38
Piper Sandler has reduced its price target for Black Diamond Therapeutics (BDTX) from $9 to $6, while reiterating an Overweight rating. This adjustment is part of Piper Sandler's broader update to its biotech models and a new biotech catalyst tracker for 2026. The firm emphasizes that BDTX remains a high-risk/high-reward investment, particularly with upcoming data on BDTX-1535 expected in the first half of 2024.
2026-02-02 15:28:14
Piper Sandler has reduced its price target for Black Diamond Therapeutics, Inc. (BDTX) from $9 to $8, maintaining an Overweight rating, following an update to its biotech models and 2026 Catalyst Tracker. Separately, Guggenheim downgraded BDTX from Buy to Neutral after solid Phase 2 data for silevertinib, citing increased risk in a planned Phase 3 glioblastoma trial and approaching a 2Q26 progression-free survival result. Black Diamond Therapeutics focuses on developing MasterKey therapies for oncology, with a pipeline targeting EGFR and other mutation-driven cancers.
2026-02-01 10:58:14
Piper Sandler recently lowered the price target for Black Diamond Therapeutics, Inc. (BDTX) to $8 from $9 while maintaining an Overweight rating, following updates to its biotech models and 2026 Catalyst Tracker. This adjustment comes after the company released positive Phase 2 data for silevertinib in NSCLC, showing robust CNS activity, though Guggenheim subsequently reduced its rating to Neutral due to increased risk for future trials. Black Diamond Therapeutics, a clinical-stage oncology company, focuses on developing MasterKey therapies for oncogenic mutations.
2026-01-27 06:58:51
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $9.33. This comes as institutional investors own 95.47% of the stock, and the company recently surpassed its quarterly EPS estimates. The firm, specializing in precision oncology, is developing small-molecule therapies targeting tumor-driving mutations.
